PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
-30.37%
Negative gross profit growth while CRVO is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
-24.83%
Negative EBIT growth while CRVO is at 78.71%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-24.83%
Negative operating income growth while CRVO is at 31.16%. Joel Greenblatt would press for urgent turnaround measures.
-17.79%
Negative net income growth while CRVO stands at 33.22%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-12.12%
Negative EPS growth while CRVO is at 33.12%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-9.09%
Negative diluted EPS growth while CRVO is at 33.12%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
5.06%
Share count expansion well above CRVO's 0.02%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.04%
Diluted share count expanding well above CRVO's 0.02%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-120.47%
Negative OCF growth while CRVO is at 31.15%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-120.93%
Negative FCF growth while CRVO is at 31.15%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-252.09%
Negative 10Y OCF/share CAGR while CRVO stands at 99.97%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
90.56%
5Y OCF/share CAGR is similar to CRVO's 99.35%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
77.71%
3Y OCF/share CAGR at 75-90% of CRVO's 94.10%. Bill Ackman would press for improvements in margin or overhead to catch up.
99.67%
Similar net income/share CAGR to CRVO's 99.99%. Walter Schloss would see parallel tailwinds or expansions for both firms.
85.97%
Positive 5Y CAGR while CRVO is negative. John Neff might view this as a strong mid-term relative advantage.
69.72%
3Y net income/share CAGR 50-75% of CRVO's 95.41%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
173.45%
10Y equity/share CAGR above 1.5x CRVO's 100.02%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-62.01%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
56.61%
Positive short-term equity growth while CRVO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-13.24%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-1.77%
We’re deleveraging while CRVO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
45.24%
We increase R&D while CRVO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-4.95%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.